Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03962543
Title MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SpringWorks Therapeutics, Inc.
Indications

plexiform neurofibroma

Therapies

PD-0325901

Age Groups: senior | child | adult
Covered Countries USA


No variant requirements are available.